RxDoctor Payments Data

Gorka Zurinaga, MD

Internal Medicine · Roswell, GANPI 1306908249

Payments from drug & device makers

$339in general payments, 2019–2025

Across 13 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$143
  • Sanofi-aventis U.S. LLC$47
  • Exact Sciences$30
  • Lilly USA, LLC$26
  • Abbott$22
  • Amgen$19
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$32797%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$339 in reported general payments places this provider in the 50th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$113,543
Medicare patients
278
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol70$59,009
OzempicSemaglutide41$52,018
JardianceEmpagliflozin46$44,282
MounjaroTirzepatide38$38,313
TrulicityDulaglutide21$37,751
EliquisApixaban19$16,188
Synjardy XrEmpagliflozin/Metformin Hcl14$15,345
MyrbetriqMirabegron11$4,990
SynthroidLevothyroxine Sodium45$4,491
Memantine Hcl74$3,939
Rosuvastatin Calcium406$3,591
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,590
Risedronate Sodium34$2,580
Atorvastatin Calcium250$2,541
Levothyroxine Sodium249$2,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$26$76,06359 claims
AstraZenecaFarxiga$17$59,00970 claims
Novo NordiskOzempic$143$52,01841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →